- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple Myeloma
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 808KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 56KB)
Bortezomib – July 2021
Bortezomib: Powder for injection 1 mg, Powder for injection 2.5 mg, Powder for injection 3 mg, Powder for injection 3.5 mg: DBL Bortezomib®
Last updated
29 October 2021